Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maximilian Shokat

Interventional Pain Medicine Thomasville, GA Doctor of Osteopathy

NPI 1659559789 CMS profile 496015

615 S Hansell St, Thomasville, GA 31792

Open in the dashboard

General payments

$7,375

262 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maximilian Shokat of Thomasville, GA is reported in the CMS Open Payments database as having received $7,375 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $490 22
2024 General $1,764 33
2023 General $932 24
2022 General $999 42
2021 General $1,358 48
2020 General $833 50
2019 General $999 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maximilian Shokat
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Maximilian Shokat were reported at $490. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Maximilian Shokat Interventional Pain Medicine median Middle half National median
2019 $999 $684 $216–$2,079 $163
2020 $833 $382 $122–$1,109 $114
2021 $1,358 $552 $167–$1,554 $132
2022 $999 $605 $187–$1,924 $149
2023 $932 $671 $195–$1,915 $160
2024 $1,764 $684 $206–$1,837 $164
2025 $490 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $3,653 113 payments
  2. Abbott Laboratories $2,063 59 payments
  3. Globus Medical, Inc. $334 15 payments
  4. Collegium Pharmaceutical, Inc. $291 19 payments
  5. Indivior Inc. $188 8 payments
  6. Pfizer Inc. $139 9 payments
  7. Medtronic, Inc. $125 5 payments
  8. Scilex Pharmaceuticals Inc. $82 5 payments
  9. Lilly USA, LLC $77 5 payments
  10. Braeburn Inc. $61 3 payments
  11. Other $364 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,481 257 payments
  2. Travel and Lodging $894 5 payments
Products named General payments · program years 2019–2025
  1. Omnia $1,311 39 payments
  2. Senza Spinal Cord Stimulator $1,248 35 payments
  3. PROCLAIM Neuromodulation $1,042 16 payments
  4. Senza Spinal Cord Stimulation System $958 37 payments
  5. Proclaim Family of SCS IPGs $348 24 payments
  6. PROCLAIM Neuromodulation $346 6 payments
  7. Senza Spinal Cord Stimulator $334 15 payments
  8. Proclaim IPG $290 12 payments
  9. XTAMPZA $217 15 payments
  10. SUBLOCADE $113 5 payments
  11. Other $1,384 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

7,703

Median for Pain Management: 951

Drug cost

$449,918

Median for Pain Management: $26,034

Branded share of claims

68%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 232 $147,647
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,698 $85,497
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,757 $60,490
Nucynta Er Tapentadol Hcl Brand 24 $36,765
Fentanyl Generic 269 $27,893
Oxycodone Hcl Generic 1,219 $22,091
Oxycontin Oxycodone Hcl Brand 35 $20,748
Hysingla Er Hydrocodone Bitartrate Brand 12 $13,093
Morphine Sulfate Er Morphine Sulfate Brand 381 $11,564
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 56 $5,861

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$476,262

Of which drugs: $3,597

Medicare patients

555

Average age 71

Services billed

5,421

330 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Diabetes 40%
Ischemic heart disease 38%
Chronic kidney disease 33%
Heart failure 28%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 194 332 $93
Injection, ketorolac tromethamine, per 15 mg J1885 Office 67 112 $54
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 183 285 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIXADI
  • Braeburn Inc. $61
$61 — —
SUBLOCADE
  • Indivior Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record